Next Generation: Cancer Drug in Disguise

Researchers develop a strategy for rendering a toxic drug harmless—until it encounters a pair of enzymes that signals cancer cells are nearby.

Written byKate Yandell
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Nobuhide Ueki in the labSTONY BROOK UNIVERSITYThe drug: Researchers have found a new way to modify cell-killing agents to make them selectively poison cancer cells, while avoiding healthy cells, according to a paper published today (November 5) in Nature Communications. The researchers deactivated a toxic agent, puromycin, by adding an acetylated lysine residue to it. The resulting compound, called Boc-KAc-Puro, is a prodrug—the compound is biologically inactive until it interacts with enzymes produced by the cancer cells it targets. The proposed activating enzymes include histone deacetylases (HDACs) and the protease cathepsin L (CTSL), which are abundant in cancer cells. To activate the drug, the HDACs first deacetylate the lysine residue. Only after the deacetylation can CTSL remove the lysine from the puromycin, freeing it to kill any nearby cells by interrupting protein synthesis. The paper “introduces a clever way of ensuring the anticancer drug activates only in designated tumors by targeting two distinctive enzymes overexpressed in cancer cells,” Seulki Lee, who studies molecular imaging and drug delivery at the Johns Hopkins School of Medicine's Center for Nanomedicine and Department of Radiology and was not involved in the study, wrote in an email to The Scientist.

What’s new: Numerous tumor-targeting prodrugs are in development. But Boc-KAc-Puro is novel because it uses HDACs as triggering enzymes, and unleashing its toxicity involves two steps rather than one. “If you only have HDAC it won’t activate the drug,” said coauthor Nobuhide Ueki, a cancer biologist at Stony Brook University on Long Island, New York. “You need both HDAC and cathepsin L.” The two-step triggering process makes it less likely that a noncancer cell could unleash the drug’s toxicity. “Since the prodrug activates and demonstrates toxicity only after meeting the two unique enzymes in cancer cells, the system demonstrates increased specificity and safety compared to conventional prodrugs targeting a single enzyme,” said Lee. The researchers found that Boc-KAc-Puro was able to kill a variety of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Image of small blue creatures called Nergals. Some have hearts above their heads, which signify friendship. There is one Nergal who is sneezing and losing health, which is denoted by minus one signs floating around it.
June 2025, Issue 1

Nergal Networks: Where Friendship Meets Infection

A citizen science game explores how social choices and networks can influence how an illness moves through a population.

View this Issue
Illustrated plasmids in bright fluorescent colors

Enhancing Elution of Plasmid DNA

cytiva logo
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo
Explore new strategies for improving plasmid DNA manufacturing workflows.

Overcoming Obstacles in Plasmid DNA Manufacturing

cytiva logo
Unraveling Complex Biology with Advanced Multiomics Technology

Unraveling Complex Biology with Five-Dimensional Multiomics

Element Bioscience Logo

Products

The Scientist Placeholder Image

Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity 

The Scientist Placeholder Image

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

agilent-logo

Agilent Announces the Enhanced 8850 Gas Chromatograph

parse-biosciences-logo

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies